Search results
Results From The WOW.Com Content Network
ELIQUIS (apixaban) This product information is intended only for residents of the United States. for Healthcare professionals: Visit www.eliquis.com for U.S. Physician Prescribing Information
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.
The FDA granted approval of the generic apixaban applications to Micro Labs Limited and Mylan Pharmaceuticals Inc. Please contact the manufacturers for information about the medicine’s...
(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS ® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Includes Eliquis side effects, interactions and indications.
Bristol Myers Squibb and Pfizer manufacture Eliquis. The medication works by blocking Factor Xa, which is a key enzyme in the blood clotting process. The drug is the latest in a new class of anticoagulants that includes Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban).